Moderna announced Tuesday it has dosed its first participant in a phase III clinical trial of a combination influenza and COVID-19 vaccine. In earlier Phase I/II clinical trials, data showed that the vaccine candidate achieved antibody levels similar or greater to the licensed standalone influenza vaccine and to Moderna's COVID vaccine. PHOTO: In this Feb. 13, 2021, file photo, the headquarters of pharmaceutical company Moderna is shown in Cambridge, Mass. Pfizer previously told investors during an earnings call in January 2023 that a successful COVID-flu combination vaccine could help increase the percentage of Americans who receive a COVID vaccine. Moderna doses 1st participant in phase 3 clinical trial of combo flu, COVID vaccine originally appeared on abcnews.go.com

Source: ABC News October 25, 2023 00:13 UTC